Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients

Gastroenterology

Volumn 152, Issue 6, 2017, Pages 1345-1357.e7

  Rosen, Michael J ^a,b   Karns, Rebekah ^a   Vallance, Jefferson E ^a   Bezold, Ramona ^a   Waddell, Amanda ^a   Collins, Margaret H ^a,b   Haberman, Yael ^a,c   Minar, Phillip ^a,b   Baldassano, Robert N ^d   Hyams, Jeffrey S ^e   Baker, Susan S ^f   Kellermayer, Richard ^g   Noe, Joshua D ^h   Griffiths, Anne M ⁱ   Rosh, Joel R ^j   Crandall, Wallace V ^k   Heyman, Melvin B ^l   Mack, David R ^m   Kappelman, Michael D ⁿ   Markowitz, James ^o   Moulton, Dedrick E ^p   Leleiko, Neal S ^q   Walters, Thomas D ⁱ   Kugathasan, Subra ^r   Wilson, Keith T ^s,t   Hogan, Simon P ^a,b   Denson, Lee A ^a,b   more..

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c SHEBA MEDICAL CENTER   (Israel)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e Division of Pediatric Infectious Diseases   (United States)

^f CHILDREN S HOSPITAL OF BUFFALO   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ HOSPITAL FOR SICK CHILDREN   (Canada)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^k NATIONWIDE CHILDREN S HOSPITAL   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

ⁿ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^o Children's Medical Center   (United States)

^p VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q HASBRO CHILDREN'S HOSPITAL   (United States)

^r EMORY UNIVERSITY   (United States)

^s VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^t VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

AUROC; Gene Expression Profile; Immune Regulation; Prognostic Factor

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CALGRANULIN; CALGRANULIN A; CHITINASE 3 LIKE PROTEIN 1; CORTICOSTEROID; EOTAXIN; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INDUCIBLE T CELL COSTIMULATOR; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23P19; INTERLEUKIN 5; MERCAPTOPURINE; MESALAZINE; MESSENGER RNA; RETINOID RELATED ORPHAN RECEPTOR ALPHA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR INHIBITOR; IL17A PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; TRANSCRIPTOME;

ADOLESCENT; ARTICLE; BIOLOGICAL THERAPY; CELLULAR IMMUNITY; CHILD; CLINICAL OUTCOME; COHORT ANALYSIS; COLITIS; COLON CROHN DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOGENETICS; INFANT; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA; MAJOR CLINICAL STUDY; MALE; MUCOSAL IMMUNITY; NEWBORN; PEDIATRICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECTUM DISEASE; RECTUM MUCOSA; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH17 CELL; TH2 CELL; TREATMENT RESPONSE; ULCER HEALING; ULCERATIVE COLITIS; UPREGULATION; AREA UNDER THE CURVE; CASE CONTROL STUDY; CLINICAL TRIAL; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; GENETICS; IMMUNOLOGY; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RECTUM;

ADOLESCENT; AREA UNDER CURVE; CASE-CONTROL STUDIES; CHILD; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; FEMALE; GENE EXPRESSION; HUMANS; IMMUNITY, MUCOSAL; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKIN-5; INTERLEUKINS; INTESTINAL MUCOSA; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECTUM; RNA, MESSENGER; ROC CURVE; TRANSCRIPTOME; UP-REGULATION;

EID: 85018815564     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.01.016     Document Type: Article

References (41)

1. 1 Fuss, I.J., Neurath, M., Boirivant, M., et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157 (1996), 1261–1270.
2. 2 Fuss, I.J., Heller, F., Boirivant, M., et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 113 (2004), 1490–1497.
3. 3 Wynn, T.A., Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol 15 (2015), 271–282.
4. 4 Heller, F., Florian, P., Bojarski, C., et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129 (2005), 550–564.
5. 5 Kappelman, M.D., Moore, K.R., Allen, J.K., et al. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci 58 (2012), 519–525.
6. 6 Adamiak, T., Walkiewicz-Jedrzejczak, D., Fish, D., et al. Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin. Inflamm Bowel Dis 19 (2013), 1218–1223.
7. 7 Winter, D.A., Karolewska-Bochenek, K., Lazowska-Przeorek, I., et al. Pediatric IBD-unclassified is less common than previously reported; results of an 8-year audit of the EUROKIDS registry. Inflamm Bowel Dis 21 (2015), 2145–2153.
8. 8 Gupta, N., Bostrom, A.G., Kirschner, B.S., et al. Presentation and disease course in early- compared to later-onset pediatric Crohn's disease. Am J Gastroenterol 103 (2008), 2092–2098.
9. 9 de Bie, C.I., Pærregaard, A., Kolacek, S., et al. Disease phenotype at diagnosis in pediatric Crohnʼs disease. Inflamm Bowel Dis 19 (2013), 378–385.
10. 10 Levine, A., Koletzko, S., Turner, D., et al. The ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 58 (2014), 795–806.
11. 11 Mosli, M.H., Feagan, B.G., Zou, G., et al. Development and validation of a histological index for UC. Gut 66 (2015), 50–58.
12. 12 Iboshi, Y., Nakamura, K., Ihara, E., et al. Multigene analysis unveils distinctive expression profiles of helper T-cell-related genes in the intestinal mucosa that discriminate between ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 20 (2014), 967–977.
13. 13 Bliss, R., Weinberg, J., Determining the probability distribution and evaluating sensitivity and false positive rate of a confounder detection method applied to logistic regression. J Biomet Biostat, 3, 2012, 142.
14. 14 Levine, A., Griffiths, A., Markowitz, J., et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 17 (2011), 1314–1321.
15. 15 Rosen, M.J., Frey, M.R., Washington, M.K., et al. STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction. Inflamm Bowel Dis 17 (2011), 2224–2234.
16. 16 Biancheri, P., Di Sabatino, A., Ammoscato, F., et al. Absence of a role for interleukin-13 in inflammatory bowel disease. Eur J Immunol 44 (2014), 370–385.
17. 17 Kadivar, K., Ruchelli, E.D., Markowitz, J.E., et al. Intestinal interleukin-13 in pediatric inflammatory bowel disease patients. Inflamm Bowel Dis 10 (2004), 593–598.
18. 18 Iboshi, Y., Nakamura, K., Fukaura, K., et al. Increased IL-17A/IL-17F expression ratio represents the key mucosal T helper/regulatory cell-related gene signature paralleling disease activity in ulcerative colitis. J Gastroenterol 52 (2017), 315–326.
19. 19 D'Ambrosio, A., Cossu, A., Amendola, A., et al. Lamina propria CD4+LAP+ regulatory T cells are increased in active ulcerative colitis but show increased IL-17 expression and reduced suppressor activity. J Crohns Colitis 10 (2016), 346–353.
20. 20 Li, J., Ueno, A., Fort Gasia, M., et al. Profiles of lamina propria T helper cell subsets discriminate between ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 22 (2016), 1779–1792.
21. 21 Verdier, J., Begue, B., Cerf-Bensussan, N., et al. Compartmentalized expression of Th1 and Th17 cytokines in pediatric inflammatory bowel diseases. Inflamm Bowel Dis 18 (2012), 1260–1266.
22. 22 Cleynen, I., Boucher, G., Jostins, L., et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet 387 (2016), 156–167.
23. 23 Rismo, R., Olsen, T., Cui, G., et al. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scand J Gastroenterol 47 (2012), 538–547.
24. 24 Arijs, I., Li, K., Toedter, G., et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 58 (2009), 1612–1619.
25. 25 Heller, F., Fuss, I.J., Nieuwenhuis, E.E., et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 17 (2002), 629–638.
26. 26 Mannon, P.J., Hornung, R.L., Yang, Z., et al. Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production. Gut 60 (2011), 449–455.
27. 27 Fuss, I.J., Joshi, B., Yang, Z., et al. IL-13R 2-bearing, type II NKT cells reactive to sulfatide self-antigen populate the mucosa of ulcerative colitis. Gut 63 (2014), 1728–1736.
28. 28 Rosen, M.J., Chaturvedi, R., Washington, M.K., et al. STAT6 deficiency ameliorates severity of oxazolone colitis by decreasing expression of claudin-2 and Th2-inducing cytokines. J Immunol 190 (2013), 1849–1858.
29. 29 Mizoguchi, A., Mizoguchi, E., Bhan, A.K., The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor alpha mutant mice. Gastroenterology 116 (1999), 320–326.
30. 30 Nguyen, D.D., Maillard, M.H., Cotta-de-Almeida, V., et al. Lymphocyte-dependent and Th2 cytokine-associated colitis in mice deficient in Wiskott-Aldrich syndrome protein. Gastroenterology 133 (2007), 1188–1197.
31. 31 Kawashima, R., Kawamura, Y.I., Oshio, T., et al. Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis. Gastroenterology 141 (2011), 2119–2129.
32. 32 Danese, S., Rudziński, J., Brandt, W., et al. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut 64 (2015), 243–249.
33. 33 Reinisch, W., Panés, J., Khurana, S., et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut 64 (2015), 894–900.
34. 34 Seno, H., Miyoshi, H., Brown, S.L., et al. Efficient colonic mucosal wound repair requires Trem2 signaling. Proc Natl Acad Sci U S A 106 (2009), 256–261.
35. 35 Webb, R.A., Hoque, T., Dimas, S., Expulsion of the gastrointestinal cestode, Hymenolepis diminuta by tolerant rats: evidence for mediation by a Th2 type immune enhanced goblet cell hyperplasia, increased mucin production and secretion. Parasite Immunol 29 (2007), 11–21.
36. 36 McKay, D.M., Khan, W.I., STAT-6 is an absolute requirement for murine rejection of Hymenolepis diminuta. J Parasitol 89 (2003), 188–189.
37. 37 Wilson, M.S., Ramalingam, T.R., Rivollier, A., et al. Colitis and intestinal inflammation in IL10-/- mice results from IL-13Rα2-mediated attenuation of IL-13 activity. Gastroenterology 140 (2011), 254–264.
38. 38 Monticelli, L.A., Osborne, L.C., Noti, M., et al. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin–EGFR interactions. Proc Natl Acad Sci U S A 112 (2015), 10762–10767.
39. 39 Young, S.-H., Antonini, J.M., Roberts, J.R., et al. Performance evaluation of cytometric bead assays for the measurement of lung cytokines in two rodent models. J Immunol Methods 331 (2008), 59–68.
40. 40 Sullivan, K.E., Cutilli, J., Piliero, L.M., et al. Measurement of cytokine secretion, intracellular protein expression, and mRNA in resting and stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 7 (2000), 920–924.
41. 41 Flores, M.G., Zhang, S., Ha, A., et al. In vitro evaluation of the effects of candidate immunosuppressive drugs: flow cytometry and quantitative real-time PCR as two independent and correlated read-outs. J Immunol Methods 289 (2004), 123–135.